doubt buy out. Not enough shares traded. News makes sense based upon previous announcements. PFE stopping A-1 mimetics makes the Brewer methods more likely to be the only winner but for apoA-1 Milano IV.
I heard somewhere that Pfizer dropped the A-1 milano because they can't produce enough on a large scale. Sembiosys is developing a new production method for A-1 milano that is projected to be available in 2016, probably a little to late for Pfizer.
Don't know if production difficulties will be an issue for LIPD - I suspect not since its a much smaller peptide.